Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(33%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
2
67%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
N/ANon-phased studies
2(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(2)

Detailed Status

Completed2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
N/A

Trials by Phase

N/A2 (100.0%)

Trials by Status

recruiting133%
completed267%

Recent Activity

1 active trials
Showing 3 of 3
recruiting

Cognitive Changes of IDH-mutant and IDH-wildtype Glioma Patients After Chemoradiotherapy With Radiation Dose to the Resting State Networks

NCT04975139
completednot_applicable

Progression of Striatal and Extrastriatal Degeneration in PD and PSP Patients

NCT03840252
completednot_applicable

Ketamine and fMRI for Neuropathic Pain

NCT02373449

Clinical Trials (3)

Showing 3 of 3 trials
NCT04975139

Cognitive Changes of IDH-mutant and IDH-wildtype Glioma Patients After Chemoradiotherapy With Radiation Dose to the Resting State Networks

Recruiting
NCT03840252Not Applicable

Progression of Striatal and Extrastriatal Degeneration in PD and PSP Patients

Completed
NCT02373449Not Applicable

Ketamine and fMRI for Neuropathic Pain

Completed

All 3 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
3